A prospective observational cohort study of covid-19 epidemiology and vaccine seroconversion in South Western Sydney, Australia, during the 2021–2022 pandemic period.

Table 3 Multivariable Binary Logistic Regression Models

Regression Models	aOR	95% CI	P
COVID-19 Diagnosis
Younger Age	0.98	0.964–0.994	0.006
Male Sex	1.7	1.093–2.701	0.019
Lower eGFR as study start	0.99	0.978–0.998	0.020
Vaccination 3 + doses	0.48	0.287–0.796	0.005
COVID-19 Hospitalisation
Older Age	1.0	1.007–1.092	0.021
eGFR at study start	0.96	0.934–0.982	< 0.001
Deceased donor graft	4.1	1.128–14.747	0.032
COVID-19 Mortality
Older Age	1.1	1.004–1.192	0.040
Respiratory disease	14.2	1.825–110.930	0.011
Current and Former Smoker	8.2	1.020-65.649	0.048
Vaccination 3 + doses	0.6	0.007–0.523	0.011
Seroconversion Subgroup
COVID-19 Diagnosis
Asian place of birth	9.0	1.803–44.888	0.007
Higher Dose of prednisolone	1.5	1.125–1.949	0.005
Seroconversion	0.1	0.025–0.627	0.011

In Model:
Diagnosis: Age, BMI, Gender, Diabetes, Pacific Place of birth, eGFR at start, Transplant vintage (months), dose of prednisolone, Tacrolimus present, Cyclosporin present, Vaccination (3 + doses)
Hospitalisation: Age, BMI, Gender, Diabetes, Pacific place of birth, eGFR at start, Haemodialysis (vs. other prior modality), Deceased donor graft (vs. other), Dose of Mycophenolate, Use of Blood thinner, Vaccination (3 + doses)
Note. Time to ATG and Peripheral vascular disease variables excluded due to model limitations of total variable number, model instability and wide confidence intervals
Mortality: Age, BMI, Gender, Diabetes, Respiratory disease, Peripheral vascular disease, Smoking status, Vaccination (3 + doses)
In Model (Seroconversion Subgroup):
Age, Place of Birth, Dose of Prednisolone, Diabetes, mTOR present, CNI present, Transplant vintage (months), Vaccination of 3 + doses, Seroconversion status

ISSN: 1471-2369